select a format

Single User License
USD 2000 INR 130060
Site License
USD 4000 INR 260120
Corporate User License
USD 6000 INR 390180

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Open-Angle Glaucoma-Pipeline Review, H2 2015

Open-Angle Glaucoma-Pipeline Review, H2 2015


  • Products Id :- GMDHC6985IDB
  • |
  • Pages: 94
  • |
  • August 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Open-Angle Glaucoma-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Open-Angle Glaucoma-Pipeline Review, H2 2015', provides an overview of the Open-Angle Glaucoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Open-Angle Glaucoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Open-Angle Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Open-Angle Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Open-Angle Glaucoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Open-Angle Glaucoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Open-Angle Glaucoma Overview 9

Therapeutics Development 10

Pipeline Products for Open-Angle Glaucoma-Overview 10

Pipeline Products for Open-Angle Glaucoma-Comparative Analysis 11

Open-Angle Glaucoma-Therapeutics under Development by Companies 12

Open-Angle Glaucoma-Therapeutics under Investigation by Universities/Institutes 14

Open-Angle Glaucoma-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Open-Angle Glaucoma-Products under Development by Companies 18

Open-Angle Glaucoma-Products under Investigation by Universities/Institutes 20

Open-Angle Glaucoma-Companies Involved in Therapeutics Development 21

Aerie Pharmaceuticals, Inc. 21

Allergan Plc 22

Amakem NV 23

Asahi Kasei Pharma Corp. 24

Bausch & Lomb Incorporated 25

F. Hoffmann-La Roche Ltd. 26

Inotek Pharmaceuticals Corporation 27

Ocular Therapeutix, Inc. 28

Ono Pharmaceutical Co., Ltd. 29

Otsuka Holdings Co., Ltd. 30

Oxford BioMedica Plc 31

Sanofi 32

Santen Pharmaceutical Co., Ltd. 33

Sun Pharmaceutical Industries Limited 34

Sylentis S.A. 35

vTv Therapeutics LLC 36

Open-Angle Glaucoma-Therapeutics Assessment 37

Assessment by Monotherapy Products 37

Assessment by Combination Products 38

Assessment by Target 39

Assessment by Mechanism of Action 41

Assessment by Route of Administration 43

Assessment by Molecule Type 45

Drug Profiles 47

(carteolol hydrochloride + latanoprost)-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

(dorzolamide hydrochloride + latanoprost)-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

(latanoprost + trabodenoson)-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

AMA-0076-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

AR-13324-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

ATS-8535-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

bamosiran-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

bimatoprost SR-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

DE-117-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Glaucoma-GT-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

HPP-851-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

latanoprost-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

latanoprost-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

latanoprost SR-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

latanoprost SR-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

latanoprostene bunod-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

ONO-9054-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

OPA-6566-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

RO-5093151-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

SAR-366234-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

Small Molecules to Antagonize CXCR3 for Glaucoma-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

trabodenoson-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

travoprost SR-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Open-Angle Glaucoma-Recent Pipeline Updates 75

Open-Angle Glaucoma-Dormant Projects 87

Open-Angle Glaucoma-Discontinued Products 88

Open-Angle Glaucoma-Product Development Milestones 89

Featured News & Press Releases 89

Mar 13, 2012: NicOx, Bausch + Lomb's Glaucoma Candidate BOL-303259-X Meets Primary Endpoint In Phase IIb Study 89

Nov 28, 2011: NicOx Announces Completion Of Patient Recruitment In Glaucoma Study 90

Mar 10, 2010: Qlt Announces Phase II Clinical Trial Results And Development Plans For The Punctal Plug Delivery System 90

Jul 28, 2009: Qlt Announces Interim Data From A Phase II Clinical Trial And A Device Study For A Punctal Plug Drug Delivery System 91

Appendix 93

Methodology 93

Coverage 93

Secondary Research 93

Primary Research 93

Expert Panel Validation 93

Contact Us 93

Disclaimer 94

List of Tables

Number of Products under Development for Open-Angle Glaucoma, H2 2015 10

Number of Products under Development for Open-Angle Glaucoma-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Number of Products under Investigation by Universities/Institutes, H2 2015 14

Comparative Analysis by Late Stage Development, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Development, H2 2015 17

Products under Development by Companies, H2 2015 18

Products under Development by Companies, H2 2015 (Contd..1) 19

Products under Investigation by Universities/Institutes, H2 2015 20

Open-Angle Glaucoma-Pipeline by Aerie Pharmaceuticals, Inc., H2 2015 21

Open-Angle Glaucoma-Pipeline by Allergan Plc, H2 2015 22

Open-Angle Glaucoma-Pipeline by Amakem NV, H2 2015 23

Open-Angle Glaucoma-Pipeline by Asahi Kasei Pharma Corp., H2 2015 24

Open-Angle Glaucoma-Pipeline by Bausch & Lomb Incorporated, H2 2015 25

Open-Angle Glaucoma-Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 26

Open-Angle Glaucoma-Pipeline by Inotek Pharmaceuticals Corporation, H2 2015 27

Open-Angle Glaucoma-Pipeline by Ocular Therapeutix, Inc., H2 2015 28

Open-Angle Glaucoma-Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 29

Open-Angle Glaucoma-Pipeline by Otsuka Holdings Co., Ltd., H2 2015 30

Open-Angle Glaucoma-Pipeline by Oxford BioMedica Plc, H2 2015 31

Open-Angle Glaucoma-Pipeline by Sanofi, H2 2015 32

Open-Angle Glaucoma-Pipeline by Santen Pharmaceutical Co., Ltd., H2 2015 33

Open-Angle Glaucoma-Pipeline by Sun Pharmaceutical Industries Limited, H2 2015 34

Open-Angle Glaucoma-Pipeline by Sylentis S.A., H2 2015 35

Open-Angle Glaucoma-Pipeline by vTv Therapeutics LLC, H2 2015 36

Assessment by Monotherapy Products, H2 2015 37

Assessment by Combination Products, H2 2015 38

Number of Products by Stage and Target, H2 2015 40

Number of Products by Stage and Mechanism of Action, H2 2015 42

Number of Products by Stage and Route of Administration, H2 2015 44

Number of Products by Stage and Molecule Type, H2 2015 46

Open-Angle Glaucoma Therapeutics-Recent Pipeline Updates, H2 2015 75

Open-Angle Glaucoma-Dormant Projects, H2 2015 87

Open-Angle Glaucoma-Discontinued Products, H2 2015 88

List of Figures

Number of Products under Development for Open-Angle Glaucoma, H2 2015 10

Number of Products under Development for Open-Angle Glaucoma-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Comparative Analysis by Late Stage Development, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Products, H2 2015 17

Assessment by Monotherapy Products, H2 2015 37

Assessment by Combination Products, H2 2015 38

Number of Products by Top 10 Targets, H2 2015 39

Number of Products by Stage and Top 10 Targets, H2 2015 39

Number of Products by Top 10 Mechanism of Actions, H2 2015 41

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 41

Number of Products by Top 10 Routes of Administration, H2 2015 43

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 43

Number of Products by Top 10 Molecule Types, H2 2015 45

Number of Products by Stage and Top 10 Molecule Types, H2 2015 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aerie Pharmaceuticals, Inc.

Allergan Plc

Amakem NV

Asahi Kasei Pharma Corp.

Bausch & Lomb Incorporated

F. Hoffmann-La Roche Ltd.

Inotek Pharmaceuticals Corporation

Ocular Therapeutix, Inc.

Ono Pharmaceutical Co., Ltd.

Otsuka Holdings Co., Ltd.

Oxford BioMedica Plc

Sanofi

Santen Pharmaceutical Co., Ltd.

Sun Pharmaceutical Industries Limited

Sylentis S.A.

vTv Therapeutics LLC

Open-Angle Glaucoma Therapeutic Products under Development, Key Players in Open-Angle Glaucoma Therapeutics, Open-Angle Glaucoma Pipeline Overview, Open-Angle Glaucoma Pipeline, Open-Angle Glaucoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com